FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies

Xembify is a 20% immune globulin solution for subcutaneous injection indicated to treat primary immunodeficiencies in patients aged 2 years and older.FDA Approvals

Source: Medscape Allergy Headlines - July 6, 2019 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Alert Source Type: news